VCANBIO(600645)2023-04-25 16:00Financial Performance - Total operating revenue for Q1 2023 was ¥377,745,248.80, a decrease of 4.4% compared to ¥394,174,107.03 in Q1 2022[22]. - Total operating costs for Q1 2023 were ¥323,064,529.03, down 3.5% from ¥335,382,040.09 in Q1 2022[22]. - Net profit for Q1 2023 was ¥35,256,628.40, a slight decrease of 2.7% from ¥36,246,721.16 in Q1 2022[23]. - The net profit attributable to shareholders for Q1 2023 was CNY 37,373,824.55, an increase of 4.33% year-over-year[30]. - The total comprehensive income for Q1 2023 was ¥23,039,552.43, compared to a loss of ¥42,196,397.05 in Q1 2022[23]. - Basic earnings per share remained stable at ¥0.08 for both Q1 2023 and Q1 2022[23]. - The company reported a basic earnings per share of CNY 0.08 for Q1 2023, unchanged from the previous year[30]. Assets and Liabilities - The total assets as of Q1 2023 were 5,247,791,551.14 RMB, a decrease from 5,284,619,414.55 RMB in the previous period[19]. - The total non-current assets were 2,950,834,014.00 RMB, down from 2,974,590,727.49 RMB[19]. - The total current liabilities decreased to 1,412,669,461.64 RMB from 1,471,494,581.46 RMB[19]. - The total liabilities amounted to ¥1,571,850,968.19, a decrease from ¥1,630,964,993.11 in the previous period[20]. - The equity attributable to shareholders of the parent company was ¥3,577,205,736.94, an increase from ¥3,555,802,379.28[20]. - The equity attributable to shareholders increased to CNY 3,577,205,736.94, reflecting a growth of 0.60% year-over-year[31]. Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 27,030,268.28, down by 10.09% compared to Q1 2022[30]. - Cash received from operating activities totaled CNY 402,970,860.77 in Q1 2023, slightly up from CNY 402,509,153.30 in Q1 2022[25]. - Cash paid for goods and services in Q1 2023 was CNY 102,356,677.01, down from CNY 106,814,353.67 in the same period last year[25]. - Investment activities generated a net cash flow of -24.44 million in the previous period, indicating an improvement of approximately 7.3%[46]. - Cash outflow from investment activities totaled 24.52 million year-over-year, representing a 33.1% increase[46]. - Cash flow from financing activities resulted in a net outflow of -8.74 million in the previous period, reflecting an 11.4% increase in outflow[46]. - The ending balance of cash and cash equivalents was 1.19 billion in the previous year[46]. Research and Development - R&D expenses increased to ¥33,453,290.77 in Q1 2023, up 15.5% from ¥29,027,540.94 in Q1 2022[22]. - Clinical trial applications for the VUM02 injection have been accepted, with approvals for two indications received in February and April 2023[15]. Other Income and Expenses - Government subsidies recognized in the current period amounted to 1,075,325.83 RMB[5]. - The impairment provision reversal for receivables and contract assets was 139,815.00 RMB[5]. - Other operating income and expenses, excluding the above items, totaled 257,734.20 RMB[5]. - The total non-recurring profit and loss items amounted to 941,882.66 RMB after tax and minority interest adjustments[5]. - The company reported a decrease in other comprehensive income after tax of ¥12,217,075.97 compared to a loss of ¥78,443,118.21 in the previous year[23].